Brought to you by 
Amgen buys Alantos Pharmaceuticals for $300mm in cash
10 Jul 2007
Executive Summary
Just two days after announcing its acquisition of Ilypsa for $420mm, Amgen has now bought Alantos Pharmaceuticals (diabetes and inflammation therapeutics) for $300mm in cash. Alantos will function as a wholly owned subsidiary of Amgen.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com